Abstract

Artificial Intelligence (AI) had transfigured different sectors in society, where the pharmaceutical sector is not an exceptional case. Pharmaceutical sectors have reached new heights with the emergence of these sophisticated technologies. The evolution of artificial intelligence in the pharmaceutical industry is in a growth phase opening the possibilities of discovering many new drugs. The diseases affecting humans are increasing tremendously whereas the drugs which are available to treat or cure are very much minimal. But this kind of scenario will not be present in the future because of the combination of artificial intelligence and the pharmaceutical industry which results in faster discovery of drugs with increased clinical outcomes. The application of artificial intelligence caused a paradigm shift in the different phases of drug discovery. Artificial intelligence can shorten the time required for each step of the drug discovery process. Many pharmaceutical companies are using AI-based drug development techniques to treat a range of illnesses, including diabetes, Parkinson’s disease, Alzheimer’s disease, OCD, and more. AI is also being used in product development to create nanorobots and nanomedicines. Only a few of AI-based medications are currently undergoing clinical trials, a sign of the growing field of AI-driven drug research. We have emphasized the use of AI in pharmaceutical product development and drug discovery in this review.